Eric Xu

Founder, CEO

 Ph.D. from Duke University/UT Southwestern Medical Center, postdoc from Massachusetts Institute of Technology

Senior Investigator at Glaxo Wellcome and GSK
Distinguished Investigator/Professor at Laboratory of Structural Sciences, Director of Center for Structural Biology and Drug Discovery, Van Andel Institute, USA Director, Key Laboratory of Receptor Research, Chinese Academy of Sciences
Director, Center for Structure & Function of Drug Targets, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Focused on the structures and drug discovery of nuclear receptors (NRs) and G protein-coupled receptors (GPCRs) 
H. Eric XU and his team have solved 16 NR structures (Total 48 NRs in humans)
Publications of > 260 SCI papers, 33 papers in Cell, Nature, Science, with > 30,000 citations n> 20 patents, including the targets such as PPARα, PPARγ/RXR, GPCRs
Participated in the development of blockbuster drugs including Advair, AVANDIA (Rosiglitazone)
Development of a next-generation asthma drug PA159 (Palo Alto, Phase 2), CS0159 for NASH/PBC/PSC/IBD; and an anti-SARS-CoV-2 small-molecule drug VV116 in Phase 3

Zhengwei Zhang

COO

Ph.D. of Biochemistry and Molecular Biology, The Second Military Medical University

Postdoc of Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Head of Biology, Palo Alto Pharmaceuticals, Inc.
Founding Partner of Cascade, responsible for overall operation of the Company in all dimensions

Jingjing Shi

Chemistry

Shengsheng Yang

Biology

 Ph.D. in biochemistry and molecular biology from Second Military Medical University. Wealth of experience in the fields of regulation of gene expression and drug screening & target validation. Before joining Cascade Pharmaceuticals, Inc, he was engaged in teaching and research in the Dept. biochemistry and molecular biology of Second Military Medical University.

Hualing Pan

DMPK

 Master’s Degree, Shanghai Institute of Materia Medica

Led and participated in the promotion of DMPK work, clinical biological sample analysis, and druggability evaluation for a large number of screened compound molecules for several IND project

Gaihong Wang

Pharmacology & Regulatory Affairs

 Postdoc, Ph.D. of Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Five years of experiences in IND filing and nonclinical evaluations
Have worked in I-Mab and Palo Alto

Rong Deng

Clinical Operation

Master of Clinical Oncology, Dalian University
10+ years experiences on Clinial Trail Operation and Project Management